0
Your cart

Your cart is empty

Books > Medicine > Other branches of medicine > Pharmacology

Buy Now

Progress in Drug Research (Paperback, Softcover reprint of the original 1st ed. 1998) Loot Price: R1,495
Discovery Miles 14 950
Progress in Drug Research (Paperback, Softcover reprint of the original 1st ed. 1998): Ernst Jucker

Progress in Drug Research (Paperback, Softcover reprint of the original 1st ed. 1998)

Ernst Jucker

Series: Progress in Drug Research, 51

 (sign in to rate)
Loot Price R1,495 Discovery Miles 14 950 | Repayment Terms: R140 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Due tothedevelopmentofdrugresistanceandotherlimitationsinthe treat- ment of AIDS patients with reverse transcriptase (RT) inhibitors like zidovu- dineandothers, itbecamenecessarytoexploreantiviralagentsactingontar- getsotherthan RT. Inthepastfewyears, hundredsofHIVproteaseinhibitoLs have been synthesized and tested. Among these protease inhibitors, saquinavir, ritonavir, indinavir and nelfinavir have been marketed during 1995-1997. In this review, emphasis is placed on the development of HIV protease inhibitors as antiviral agents against HIV, structure-activity rela- tionship (SAR) analysis ofsaquinavirand relatedcompounds, comparisonof four marketed HIV protease inhibitors, and future prospect in developing new anti-HIV drugs. 2 Introduction HIV protease inhibitors 3 HIV protease as a target for chemotherapy HIV protease was first suggested as a potential target for AIDS therapy by Kramer et a1. in 1986 [5]. HIV protease is a proteolytic enzyme responsible for cleaving large numbers of amino acid sequences. This enzyme regulates conversionoftheselargeaminoacid sequencesintobiologicallyactive struc- tural and functional protein products. Specifically, HIV protease is responsi- the enzymatic processing of the gagand gag-pol genes of HIV, which ble for encode for functional core proteins and viral enzymes (reverse transcriptase, ribonuclease H, integrase, and HIV protease). The polyproteins encoded by the gagand gag-pol genes undergo post-translational processing by HIV pro- tease to form functional protein products as the viral particles budding out from infected cells. Therefore, inhibition of HIV protease by a protease inhibitor results in the release ofimmature, noninfectious viral particles [4].

General

Imprint: Birkhauser Verlag AG
Country of origin: Switzerland
Series: Progress in Drug Research, 51
Release date: November 2011
First published: 1998
Authors: Ernst Jucker
Dimensions: 244 x 170 x 18mm (L x W x T)
Format: Paperback
Pages: 326
Edition: Softcover reprint of the original 1st ed. 1998
ISBN-13: 978-3-03-489798-3
Categories: Books > Medicine > Nursing & ancillary services > Pharmacy / dispensing
Books > Medicine > Other branches of medicine > Pharmacology > General
LSN: 3-03-489798-7
Barcode: 9783034897983

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners